Cite
HARVARD Citation
Kurebe, H. et al. (n.d.). 540PClinical outcomes in non–small cell lung cancer patients with ultra-high expression of programmed death ligand-1 treated with pembrolizumab as first-line therapy: A retrospective multicenter cohort study. Annals of oncology. p. . [Online].